

Psittacosis: a comprehensive exploration and research framework from 1879 to 2024

Margret Chandira Rajappa^{1*}, Dominic Antonysamy², Vignesh Vezhaventhan¹,
Ranjith Kumar Sivaji¹, Karthikeyan Muthumani¹, Sanjay Gnana Moorthi¹,
Nagasubramanian Venkatasubramaniam¹

¹ Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Vinayaka Missions Research Foundation (DU), Tamil Nadu, India

² Department of Engineering, Sona College of Technology, Tamil Nadu, India

Article type:

Mini review article

Keywords:

Diagnostic methods
Disease prevention
Public health
Psittacosis

Article history:

Received:

December 1, 2024

Revised:

December 30, 2024

Accepted:

January 19, 2025

Available online:

May 10, 2025

Abstract

Psittacosis, or parrot fever, is a zoonotic infection caused by the bacterium, primarily affecting avian species and posing a significant threat to human health. This review comprehensively examines psittacosis, tracing its history from the late 19th century to the modern challenges encountered in the 21st century. It examines the bacterium's etiology, transmission pathways, clinical manifestations, diagnostic methodologies, and preventive strategies critical for managing this infection. Moreover, this article proposes a comprehensive research framework to enhance our understanding of psittacosis and its implications for public health, emphasizing the importance of interdisciplinary collaboration in tackling this disease. By integrating historical context with modern scientific insights, this review aims to inform future research efforts and improve preventive measures for both avian and human populations.

Introduction

Psittacosis, also known as parrot fever, is a notable zoonotic disease caused by the bacterium *Chlamydia psittaci* (1). This pathogen, primarily affecting avian species such as parrots, pigeons, and doves, has captured significant attention due to its

ability to transmit to humans, resulting in various respiratory illnesses. The historical and ongoing impact of psittacosis underscores its relevance in veterinary and human medicine, making it a critical subject for comprehensive review and research (2). In the late 19th century, psittacosis was first

*Corresponding author: mchandira172@gmail.com

<https://doi.org/10.22034/jzd.2025.19786>

https://jzd.tabrizu.ac.ir/article_19786.html

Cite this article: Rajappa M.C., Antonysamy D., Vezhaventhan V., Sivaji R.K., Muthumani K., Moorthi S.G., Venkatasubramaniam N. Psittacosis: a comprehensive exploration and research framework from 1879 to 2024. *Journal of Zoonotic Diseases*, 2025, x-x
Copyright© 2025, Published by the University of Tabriz.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY NC)



documented when human respiratory illnesses in were linked to pet parrots exhibiting similar symptoms (3). This initial recognition set the stage for understanding psittacosis as a zoonotic condition, wherein diseases are transmitted from animals to humans. Since its discovery, advancements in microbiology, epidemiology, and clinical diagnostics have significantly enhanced our understanding of psittacosis, yet challenges remain in managing and controlling this infection (4). The causative agent of psittacosis is a Gram-negative, obligate intracellular bacterium. It possesses a unique life cycle that includes two primary forms: the infectious, environmentally resilient elementary body and the reticulate body, which reproduces inside host cells (5). This life cycle facilitates the bacterium's transmission and persistence in various environments, particularly in bird droppings and feathers. The ability to remain viable outside the host for extended periods poses a significant risk for human infection, particularly in environments where birds are kept in high densities or poor sanitary conditions (6).

Human infection typically occurs by inhaling aerosolized particles from bird droppings, feathers, or respiratory secretions. The disease's transmission dynamics are influenced by several factors, including the concentration of infectious particles, exposure duration, and environmental conditions (7). Understanding these factors is crucial for developing effective prevention and control strategies. Clinically, psittacosis presents as a respiratory illness with symptoms ranging from mild flu-like symptoms to severe pneumonia. In some cases, the infection can lead to systemic complications, highlighting the importance of early detection and appropriate treatment (8). The variability in clinical presentation complicates diagnosis, often leading to delays in treatment and increased risk of severe outcomes. The impact of psittacosis extends beyond individual health concerns, affecting public health systems and veterinary practices (9). Effective disease management requires both clinical treatment and

comprehensive preventive, including hygiene practices, quarantine protocols, and public education. Additionally, ongoing research into the epidemiology, pathogenesis, and treatment of psittacosis is essential for improving disease control and reducing its impact on human and avian populations (10).

Historical Context and Epidemiological Overview

The emergence of psittacosis as a recognized disease dates back to the late 19th century. The earliest documented cases of the disease were reported in the 1870s, when clinicians observed a pattern of respiratory illness in humans linked to infected pet parrots (11). This initial recognition was pivotal in identifying psittacosis as a zoonotic disease and highlighted the need for a systematic understanding of its epidemiology.

In the late 19th and early 20th centuries, psittacosis was primarily identified in sporadic cases. During this period, the disease was often called "parrot fever," reflecting its association with pet birds (12). Limited diagnostic tools and a lack of comprehensive surveillance meant that many cases went unreported or misdiagnosed. Epidemiological data from this era indicate that psittacosis was relatively uncommon but did occur with notable severity in some cases (13). The disease was often observed in individuals with direct contact with infected birds, particularly those involved in the pet bird trade.

The mid-20th century, saw significant advancements in microbiology and diagnostic techniques. The identification of the causative agent of psittacosis marked a main breakthrough (14). This period was characterized by an increase in awareness and reporting of psittacosis cases, driven by improved diagnostic methods, including serological tests and later molecular techniques. During this time, psittacosis outbreaks were documented worldwide, with notable cases in industrialized and developing countries (15).

Contemporary Trends and Data (1970s-2024)

From the 1970s onwards, enhanced surveillance systems and public health initiatives led to more systematic reporting and monitoring of psittacosis cases. The disease became more clearly understood as a significant public health issue due to its zoonotic potential and its risk to individuals handling birds (16). Epidemiological data from this period reflect a steady number of reported cases, with occasional outbreaks linked to large-scale bird trade or poor hygiene practices in bird-keeping environments.

The 1990s and early 2000s saw the implementation of more robust surveillance systems, including national and international reporting mechanisms (17). During this time, researchers also began to investigate the global distribution of psittacosis, revealing a pattern of higher incidence in regions with significant bird populations or intensive bird trading activities. Data from these decades highlighted the need for better preventive measures

and public awareness campaigns (18). In the 21st century, advancements in molecular diagnostics, such as Polymerase chain reaction (PCR), have revolutionized the detection and reporting of psittacosis. These technologies have improved the accuracy of diagnoses and enabled more comprehensive epidemiological studies (19). Recent data indicate fluctuations in the incidence of psittacosis, influenced by factors such as changes in bird trade regulations, improved hygiene practices, and increased public awareness.

From 2000 to 2024, the global incidence of psittacosis has been marked by sporadic outbreaks and case clusters, often linked to specific events or changes in bird-keeping practices (20). For example, outbreaks have been documented in areas with new or intensified bird-keeping activities, reflecting the continued importance of monitoring and controlling the disease in high-risk environments (21).




Fig 1. Psittacosis outbreak across selected countries (1879-2024)

Trends and Observations

The historical data reveal a steady increase in reported cases of psittacosis over the past century. This trend can be attributed to several factors, including the increased popularity of pet birds, global trade in avian species, and improved diagnostic capabilities (22). The rise in cases also reflects enhanced surveillance and reporting mechanisms, which have allowed for better detection and documentation of the disease. The data suggest that while the overall incidence of psittacosis has increased, advancements in treatment and prevention have led to decreased mortality rates over time (23).

Etiology and Transmission

The Pathogen is a Gram-negative, obligate intracellular bacterium known for its complex life cycle. The bacterium exists in two primary forms:

- Elementary Body (EB) is highly infectious and resistant to environmental stresses. It is responsible for the transmission of the disease (24).
- Reticulate Body (RB) is metabolically active and replicates within the host cell. The reticulate body disrupts normal cellular functions and eventually causes cell death.

The ability of *Chlamydia psittaci* to alternate between these forms allows it to infect avian hosts effectively and subsequently pose a risk to humans.

Transmission Dynamics

Human infection primarily occurs by inhaling aerosols containing infectious particles from bird droppings, feathers, or secretions (25). Direct contact with infected birds or their contaminated environment is another significant transmission route. The bacterium's capacity to persist in dried droppings and feathers extends the risk of exposure, particularly in environments with high bird densities or poor ventilation (26).

Key Factors in Transmission

- The specific quantity of *Chlamydia psittaci* to cause human infection is not well-defined. However, higher exposure levels

are generally associated with a greater disease risk (27).

- The bacterium can remain viable in environmental reservoirs for extended periods, contributing to prolonged infection risks.

Pathophysiology of Psittacosis

The pathophysiology of psittacosis unfolds through a series of intricate stages, highlighting the dynamic interplay between the bacterium and the host's immune system. Understanding these stages provides insight into how the infection develops and the potential outcomes for affected individuals (28).

Entry and Infection

The initial phase of psittacosis begins when *Chlamydia psittaci* is transmitted to humans, typically through inhalation of aerosols containing the infectious elementary bodies (29). These elementary bodies, which are the infectious form of the bacterium, enter the respiratory tract and are phagocytized by epithelial cells lining the airways. Once inside the host cells, the elementary bodies are encapsulated within a membrane-bound vacuole (30).

Intracellular Replication

Within the protective confines of the vacuole, *Chlamydia psittaci* transforms reticulate bodies, which are the metabolically active form of the bacterium. These reticulate bodies begin to replicate extensively (31). The replication process disrupts normal cellular functions by hijacking the host's cellular machinery, leading to significant cellular damage and eventual cell death. This stage is crucial as it establishes the infection within the host and facilitates the bacterium's spread (32).

Immune Response

In response to the infection, the host's immune system activates innate and adaptive mechanisms. The innate immune response involves the activation of macrophages and the release of inflammatory cytokines, which aim to control the infection and

limit its spread (33). The adaptive immune response, involving T and B lymphocytes, further contributes to resolving the infection. A robust and timely immune response is essential for preventing systemic dissemination of the bacterium and minimizing the severity of the disease (34).

Systemic Effects

If the infection is not adequately controlled, *Chlamydia psittaci* can disseminate beyond the lungs, resulting in systemic symptoms. These can

include severe respiratory complications such as pneumonia, which may present with chest pain, difficulty breathing, and potentially life-threatening outcomes if untreated (35). In some cases, the infection can lead to respiratory failure and, rarely, death. The severity of the disease often correlates with the host's immune status and the level of exposure to the bacterium, with individuals who have compromised immune systems or pre-existing health conditions higher risk (36).




Fig. 2. Pathophysiology of psittacosis

Human Symptoms

Psittacosis typically presents as a respiratory illness with symptoms similar to influenza. The clinical manifestations may include:

- Initial symptoms often include fever, cough, and myalgia, which may be mistaken for a common cold or influenza (37).
- In more severe cases, psittacosis can progress to pneumonia, characterized by chest pain, shortness of breath, and a

productive cough. If not treated promptly, it can lead to significant respiratory distress and complications (38).

- Alongside respiratory symptoms, patients may experience headaches, gastrointestinal disturbances, and muscle pain (39).

The severity of symptoms can be influenced by factors such as the host's immune status and the level of exposure to the pathogen.

Table 1. Key features of diagnostic methods

S. No	Diagnostic method	Test type	Sample required	Utility	Advantages	Limitations	Ref No
Serological Tests							
1	ELISA	Antibody detection	Blood	Detects antibodies against, indicating recent or past infection	Simple, effective, widely used	Cannot differentiate between recent and past infections	40
2	Complement Fixation Test	Antibody detection	Blood	Measures the ability of antibodies to fix complement proteins	Historically significant	Complex, reduced sensitivity, less common	41
Molecular Diagnostics							
3	PCR	DNA amplification	Blood, sputum	Detects DNA with high sensitivity and specificity	Rapid, accurate, highly sensitive	Requires specialized equipment	42
Culture Techniques							
4	Bacterial Culture	Culture	Clinical samples (e.g. sputum)	Cultures bacteria for research purposes, offering insights into pathogen characteristics	Valuable for research	Difficult to culture due to fastidious nature	43
Imaging							
5	Chest X-ray	Radiographic imaging	N/A	Assesses pulmonary involvement (e.g. pneumonia), valid in combination with other diagnostic tests	Supportive evidence in cases of pneumonia	Non-specific, requires combination with other tests	44

Preventive Strategies

- Regular cleaning and disinfection of bird enclosures and feeding equipment are essential for minimizing contamination risks. This practice helps reduce the likelihood of pathogen persistence in the environment (45).
- When handling birds or cleaning their habitats, using gloves, masks, and protective clothing is crucial for preventing direct exposure to infectious materials (46).

Monitoring new birds should be quarantined and monitored for signs of illness before being introduced into established flocks. This practice

helps prevent the spread of disease within bird populations (47).

Public Awareness Campaigns Educating bird owners and handlers about the risks of psittacosis and the importance of veterinary consultation can help reduce the incidence of the disease (48). Public awareness campaigns play a critical role in promoting preventive measures.

Regular Veterinary Check-ups implementing routine health screenings for pet birds, including testing, is essential for early identification and management of infections (49).

A structured approach to studying zoonotic diseases like psittacosis is crucial for advancing our understanding and control of these infections (50).

The following research methodologies are recommended:

Epidemiological Research

- Monitoring psittacosis cases helps understand the disease's prevalence, incidence, and risk factors. Surveillance systems should be robust and capable of capturing data from diverse sources (51).
- Conducting surveys among bird owners and handlers can assess exposure risks and infection rates. These surveys provide valuable information for identifying at-risk populations and designing targeted interventions (52).
- Investigating outbreaks to identify sources of infection, transmission dynamics, and effective control measures is essential for managing and mitigating the impact of psittacosis (53).

Experimental Studies

- Using animal models to study the mechanisms by which pathogen causes disease and interacts with the host can provide insights into the infection process and potential therapeutic targets (54).
- Exploring potential vaccines and evaluating their efficacy in preclinical and clinical settings is critical for developing preventive strategies against psittacosis (55).
- Ensuring that animal research adheres to ethical guidelines and welfare considerations is essential for the responsible conduct of research (56).

Environmental Assessment

- Collecting and analyzing environmental samples from bird habitats helps identify contamination sources and assess the extent of infection. This information can guide hygiene practices and reduce environmental transmission (57).
- Regular monitoring of environmental contamination can inform public health strategies and prevent the spread of psittacosis (58).

Clinical Trials

- Evaluating new diagnostic tools and treatment protocols through rigorous clinical trials, including randomized controlled trials (RCTs), is essential for improving disease management (59).
- Measuring clinical outcomes to evaluate the effectiveness of new interventions ensures that treatments and diagnostic methods are effective and beneficial (60-62).

Public Health Interventions

- Developing and promoting vaccination programs for birds, alongside public health initiatives to reduce psittacosis transmission, can effectively control the disease. Effective communication and engagement with the public are key to successful prevention efforts (63, 64).
- Formulating policies and guidelines for managing and controlling psittacosis outbreaks is crucial for ensuring a coordinated and effective response to the disease (65).

Conclusion

Psittacosis remains a significant zoonotic disease with substantial implications for avian and human health. A comprehensive understanding of its etiology, transmission, clinical presentation, and preventive measures is essential for effective disease management. By employing robust diagnostic techniques, preventive strategies, and research methodologies, we can more effectively address psittacosis and mitigate its impact. Continued research and public health initiatives are crucial for controlling this disease and safeguarding animal and human populations. Advancements in diagnostics, prevention, and treatment will be pivotal in managing psittacosis and improving overall health outcomes. This review serves as a foundational reference for researchers, clinicians, and public health professionals working towards a better understanding of psittacosis and its management. The proposed research framework emphasizes the need for collaborative efforts to

effectively address the challenges posed by this zoonotic disease.

Future research should focus on developing novel vaccines, improved diagnostic tools, and enhanced public health strategies to further reduce the incidence of psittacosis and protect avian and human populations from its impact. This review article provides a comprehensive overview of psittacosis, integrating historical data, current knowledge, and future research directions to offer a detailed understanding of this significant zoonotic disease.

Acknowledgments

The authors are deeply grateful to the principal of Vinayaka Mission's College of Pharmacy, for giving us the support to accomplish this review work.

Conflicts of Interest

There are no conflicts of interest.

Ethical Approval

Not Applicable.

References

- Heddema ER, van Hannen EJ, Bongaerts M, Dijkstra F, Ten Hove RJ, de Wever B, et al. Typing of *Chlamydia psittaci* to monitor epidemiology of psittacosis and aid disease control in the Netherlands, 2008 to 2013. *Euro Surveill.* 2015;20(5):21026. <https://doi.org/10.2807/1560-7917.ES2015.20.5.21026>
- Gaede W, Reckling KF, Dresenkamp B, Kenklies S, Schubert E, Noack U, et al. *Chlamydia psittaci* Infections in Humans during an Outbreak of Psittacosis from Poultry in Germany. *Zoonoses Public Health.* 2008;55(4):184. <https://doi.org/10.1111/j.1863-2378.2008.01108.x>
- Laroucau K, Aaziz R, Meurice L, Servas V, Chossat I, Royer H, et al. Outbreak of psittacosis in a group of women exposed to *Chlamydia psittaci*-infected chickens. *Euro Surveill.* 2015;20(24): 21155. <https://doi.org/10.2807/1560-7917.ES2015.20.24.21155>
- Nieuwenhuizen AA, Dijkstra F, Notermans DW, van der Hoek W. Laboratory methods for case finding in human psittacosis outbreaks: a systematic review. *BMC Infect Dis.* 2018;18(1):442. <https://doi.org/10.1186/s12879-018-3317-7>
- Balsamo G, Maxted AM, Midla JW, Murphy JM, Wohrle R, Edling TM, et al. Compendium of Measures to Control Chlamydia psittaci Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis). *J Avian Med Surg.* 2017;31(3):262–282. <https://doi.org/10.1647/217-265>
- Knittler MR, Sachse K. *Chlamydia psittaci*: Update on an underestimated zoonotic agent. *Pathog Dis.* 2015;73(1):1–15. <https://doi.org/10.1093/femspd/ftu007>
- De Boeck C, Dehollogne C, Dumont A, Spierenburg M, Heijne M, Gyssens I, et al. Managing a cluster outbreak of psittacosis in Belgium linked to a pet shop visit in The Netherlands. *Epidemiol Infect.* 2016;144(8):1710–1716. <https://doi.org/10.1017/S0950268815003106>
- Hogerwerf L, De Gier B, Baan B, van der Hoek W. *Chlamydia psittaci* (psittacosis). as a cause of community-acquired pneumonia: a systematic review and meta-analysis. *Epidemiol Infect.* 2017;145(15):3096–3105. <https://doi.org/10.1017/S0950268817002060>
- Mair-Jenkins J, Lamming T, Dziadosz A, Flecknoe D, Stubington T, Mentasti M, et al. A psittacosis outbreak among English office workers with little or no contact with birds, August 2015. *PLoS Curr.* 2018. <https://doi.org/10.1371/currents.outbreaks.b646c3bb2b4f0e3397183f31823bbca6>
- Pether JV, Noah ND, Lau YK, Taylor JA, Bowie JC. An outbreak of psittacosis in a boys' boarding school. *J Hyg (Lond).* 1984;92(3):337–343. <https://doi.org/10.1017/S002217240006455X>
- McGuigan CC, McIntyre PG, Templeton K. Psittacosis outbreak in Tayside, Scotland, December 2011 to February 2012. *Euro Surveill.* 2012;17(22):20186. <https://doi.org/10.2807/ese.17.22.20186-en>
- Cheng YJ, Lin KY, Chen CC, Huang YL, Liu CE, Li SY. Zoonotic atypical pneumonia due to *Chlamydia psittaci*: First reported psittacosis case in Taiwan. *J Formos Med*

- Assoc. 2013;112(7):430–433.
<https://doi.org/10.1016/j.jfma.2012.08.017>
13. De Gier B, Hogerwerf L, Dijkstra F, van der Hoek W. Disease burden of psittacosis in the Netherlands. *Epidemiol Infect*. 2018;146(3):303–305.
<https://doi.org/10.1017/S0950268817003065>
 14. Rybarczyk J, Versteede C, Lernout T, Vanrompay D. Human psittacosis: A review with emphasis on surveillance in Belgium. *Acta Clin Belg*. 2019;74(1):42–48.
<https://doi.org/10.1080/17843286.2019.1590889>
 15. Grimes JE. Zoonoses acquired from pet birds. *Vet Clin North Am Small Anim Pract*. 1987;17:209–218.
[https://doi.org/10.1016/s0195-5616\(87\).50613-1](https://doi.org/10.1016/s0195-5616(87).50613-1)
 16. Heddema ER, Van Hannen EJ, Duim B, Vandenbroucke-Grauls CM, Pannekoek Y. Genotyping of *Chlamydophila psittaci* in human samples. *Emerg Infect Dis*. 2006;12(12):1989.
<https://doi.org/10.3201/eid1212.051633>
 17. Ito I, Ishida T, Mishima M, Osawa M, Arita M, Hashimoto T, et al. Familial cases of psittacosis: possible person-to-person transmission. *Intern Med*. 2002;41:580–583.
<https://doi.org/10.2169/internalmedicine.41.580>
 18. Yung AP, Grayson ML. Psittacosis—a review of 135 cases. *Med J Aust*. 1988;148:228–233.
<https://doi.org/10.5694/j.1326-5377.1988.tb99430.x>
 19. Hughes P, Chidley K, Cowie J. Neurological complications in psittacosis: a case report and literature review. *Respir Med*. 1995;89:637–638. [https://doi.org/10.1016/0954-6111\(95\).90236-8](https://doi.org/10.1016/0954-6111(95).90236-8)
 20. Newton P, Lalvani A, Conlon CP. Psittacosis associated with bilateral 4th cranial nerve palsies. *J Infect*. 1996;32:63–65.
[https://doi.org/10.1016/s0163-4453\(96\).80011-9](https://doi.org/10.1016/s0163-4453(96).80011-9)
 21. Byrom NP, Walls J, Mair HJ. Fulminant psittacosis. *Lancet*. 1979;1:353–356.
[https://doi.org/10.1016/s0140-6736\(79\).92892-7](https://doi.org/10.1016/s0140-6736(79).92892-7)
 22. Lanham JG, Doyle DV. Reactive arthritis following psittacosis. *Br J Rheumatol*. 1984;23:225–226.
<https://doi.org/10.1093/rheumatology/23.3.225>
 23. Tsapas G, Klonizakis I, Casakos K, Koncouris L. Psittacosis and arthritis. *Chemotherapy*. 1991;37:143–145.
<https://doi.org/10.1159/000238846>
 24. Verweij PE, Meis JF, Eijk R, Melchers WJ, Galama JM. Severe human psittacosis requiring artificial ventilation: case report and review. *Clin Infect Dis*. 1995;20:440–442.
<https://doi.org/10.1093/clinids/20.2.440>
 25. Petrovay F, Balla E. Two fatal cases of psittacosis caused by *Chlamydophila psittaci*. *J Med Microbiol*. 2008;57:1296–1298.
<https://doi.org/10.1099/jmm.0.2008/001578-0>
 26. Hamilton DV. Psittacosis and disseminated intravascular coagulation. *Br Med J*. 1975;2:370.
<https://doi.org/10.1136/bmj.2.5967.370>
 27. Borel N, Polkinghorne A, Pospischil A. A review on chlamydial diseases in animals: still a challenge for pathologists? *Vet Pathol*. 2018 May;55(3):374–90.
<https://doi.org/10.1177/0300985817751218>
 28. Gitsels A, Van Lent S, Sanders N, Vanrompay D. Chlamydia: what is on the outside does matter. *Crit Rev Microbiol*. 2020;46(1):100–119.
<https://doi.org/10.1080/1040841X.2020.1730300>
 29. Wang J, Wang B, Xiao J, Chen Y, Wang C. *Chlamydia psittaci*: A zoonotic pathogen causing avian chlamydiosis and psittacosis. *Virulence*. 2024;15(1).
<https://doi.org/10.1080/21505594.2024.2428411>
 30. Martens-Koop A, Thakur A. Intracellular Pathogens: Infection, Immunity, and Intervention. *Methods Mol Biol*. 2024;2813:1–17. https://doi.org/10.1007/978-1-0716-3890-3_1
 31. Yang S, Zeng J, Yu J, Sun R, Tuo Y, Bai H. Insights into Chlamydia Development and Host Cells Response. *Microorganisms*. 2024;12(7):1302. <https://doi.org/10.3390/microrganisms12071302>
 32. Benedetti F, Curreli S, Gallo RC, Zella D. Tampering of viruses and bacteria with host DNA repair: Implications for cellular transformation. *Cancers*.

- 2021;13(2):241. <https://doi.org/10.3390/cancers13020241>
33. Yang H, Sun P, et al. Chlamydia psittaci infection induces IFN-I and IL-1 β through the cGAS-STING-IRF3/NLRP3 pathway via mitochondrial oxidative stress in human macrophages. *Vet Microbiol.* 2024;289:1102-92. <https://doi.org/10.1016/j.vetmic.2024.110292>
 34. Muruganandah V, Kupz A. Immune responses to bacterial lung infections and their implications for vaccination. *Int Immunol.* 2022;34(5):231-248. <https://doi.org/10.1093/intimm/dxab109>
 35. Zhou Y, Zou Y, et al. Acute respiratory distress syndrome caused by Chlamydia psittaci pneumonia: a case report and literature review. *Front Med.* 2024;11:1418241. <https://doi.org/10.3389/fmed.2024.1418241>
 36. Nieuwenhuizen AA, Dijkstra F, Notermans DW, van der Hoek W. Laboratory methods for case finding in human psittacosis outbreaks: a systematic review. *BMC Infect Dis.* 2018;18:1-6. <https://doi.org/10.1186/s12879-018-3115-0>
 37. Boseret G, Losson B, Mainil JG, Thiry E, Saegerman C. Zoonoses in pet birds: review and perspectives. *Vet Res.* 2013;44:1-7. <https://doi.org/10.1186/1297-9716-44-36>
 38. Zuzek R, Green M, May S. Severe psittacosis progressing to suspected organizing pneumonia and the role of corticosteroids. *Respir Med Case Rep.* 2021;34: 101486. <https://doi.org/10.1016/j.rmcr.2021.101486>
 39. Zhu Z, Wang X, Zhao J, Xie Z, Yang C, Li L, et al. Clinical Characteristics of Six Patients with *Chlamydia psittaci* Infection Diagnosed by Metagenomic Next-Generation Sequencing: A Case Series. *Infect Drug Resist.* 2023;16:869-878. <https://doi.org/10.2147/IDR.S393195>
 40. Madani SA, Peighambari SM. PCR-based diagnosis, molecular characterization and detection of atypical strains of avian Chlamydia psittaci in companion and wild birds. *Avian Pathol.* 2013;42(1):38-44. <https://doi.org/10.1080/03079457.2012.757288>
 41. Mazzulli T. Laboratory Diagnosis of Infection Due to Viruses, Chlamydia, Chlamydocytophila and Mycoplasma. *Principles and Practice of Pediatric Infectious Diseases.* 2012:1384-1399.e8. <https://doi.org/10.1016/B978-1-4377-2702-9.00289-0>
 42. Boivin G, Mazzulli T, Petric M, Couillard M. Diagnosis of Viral Infections. In: Richman DD, Whitely RJ, Hayden FG, editors. *Clinical Virology.* 4th ed. Washington D.C: ASM Press; -preview-2016-12-31. p. 291-319.
 43. Hogerwerf L, Roof I, de Jong MJ, Dijkstra F, van der Hoek W. "Animal sources for zoonotic transmission of psittacosis: a systematic review." *BMC Infect Dis.* 2020;20:1-4. <https://doi.org/10.1186/s12879-020-4918-y>
 44. Stewardson AJ, Grayson ML. "Psittacosis." *Infect Dis Clin North Am.* 2010;24(1):7-25. <https://doi.org/10.1016/j.idc.2009.10.003>
 45. Dembek ZF, Mothershead JL, Owens AN, Chekol T, Wu A. "Psittacosis: an underappreciated and often undiagnosed disease." *Pathogens.* 2023;12(9):1165. <https://doi.org/10.3390/pathogens12091165>
 46. Abdullah A, Ardiansyah A. Parrot trade and the potential risk of psittacosis as a zoonotic disease in Indonesian bird markets. *Birds.* 2024;5(1):137-154. <https://doi.org/10.3390/birds5010010>
 47. Wang J, Wang B, Xiao J, Chen Y, Wang C. Chlamydia psittaci: A zoonotic pathogen causing avian chlamydiosis and psittacosis. *Virulence.* 2024;15(1):2428411. <https://doi.org/10.1080/21505594.2024.2428411>
 48. Lu Y, Gai W, Li M, Zheng Y, Zhang X, Zhou Y, et al. "Psittacosis pneumonia features, distinguishing characteristics, and outcomes: A retrospective study." *Infect Drug Resist.* 2024;17:5523-5533. <https://doi.org/10.2147/IDR.S482471>
 49. Boseret G, Losson B, Mainil JG, Thiry E, Saegerman C. Zoonoses in pet birds: review and perspectives. *Vet Res.* 2013;44:36. <https://doi.org/10.1186/1297-9716-44-36>
 50. Hogerwerf L, De Gier B, Baan B, Van Der Hoek W. "Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis." *Epidemiol Infect.* 2017;145(15):3096-3105. <https://doi.org/10.1017/S0950268817002060>

51. Rybarczyk J, Versteede C, Lernout T, Vanrompay D. Human psittacosis: a review with emphasis on surveillance in Belgium. *Acta Clin Belg.* 2020;75(1):42-48. <https://doi.org/10.1080/17843286.2019.1590889>
52. Catalan Saenz HS, Cruz-Ausejo L. Preventive, safety and control measures against Avian Influenza A (H5N1) in occupationally exposed groups: A scoping review. *One Health.* 2024;100766. <https://doi.org/10.1016/j.onehlt.2024.100766>
53. Committee CML, Association CH. "Chinese expert consensus on diagnosis and treatment of psittacosis." *Chinese J Clin Infectious Dis.* 2024;17(3):191-204. <https://doi.org/10.3760/cma.j.issn.1674-2397.2024.03.002>
54. Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. *Nat Rev Microbiol.* 2010;8:564–577. <https://doi.org/10.1038/nrmicro2403>
55. Hitchcock PJ. Future directions of chlamydial research. *Chlamydia: Intracellular Biology, Pathogenesis, and Immunity.* 1999;297-311. <https://doi.org/10.1128/9781555818203.ch10>
56. Fenton A. Holding Animal-Based Research to Our Highest Ethical Standards: Re-seeing Two Emergent Laboratory Practices and the Ethical Significance of Research Animal Dissent. *ILAR J.* 2019;60(3):397–403. <https://doi.org/10.1093/ilar/ilaa014>
57. Boseret G, Losson B, Mainil JG, Thiry E, Saegerman C. Zoonoses in pet birds: review and perspectives. *Vet Res.* 2013;44:36. <https://doi.org/10.1186/1297-9716-44-36>
58. Hogerwerf L, Roof I, et al. "Animal sources for zoonotic transmission of psittacosis: a systematic review." *BMC Infect Dis.* 2020;20(1):192. <https://doi.org/10.1186/s12879-020-4918-y>
59. Saturni S, Bellini F, Braidò F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. *Pulm Pharmacol Ther.* 2014;27(2):129–138. <https://doi.org/10.1016/j.pupt.2014.01.005>
60. Nieuwenhuizen AA, Dijkstra F, et al. "Laboratory methods for case finding in human psittacosis outbreaks: a systematic review." *BMC Infect Dis.* 2018;18(1):442. <https://doi.org/10.1186/s12879-018-3317-0>
61. Khadka S, Timilsina B, et al. "Importance of clinical history in the diagnosis of psittacosis: a case report." *Ann Med Surg.* 2022;82:104695. <https://doi.org/10.1016/j.amsu.2022.104695>
62. Xu D, Qian A. "A case of severe psittacosis pneumonia with multi organ insufficiency and meningitis." *Chin J Emerg Med.* 2023;32(1):109-112. <https://doi.org/10.1186/s40064-016-2592-8>
63. Shi Y, Chen J, Shi X, Hu J, Li H, Li X, et al. A case of *Chlamydia psittaci* caused severe pneumonia and meningitis diagnosed by metagenome next-generation sequencing and clinical analysis: a case report and literature review. *BMC Infect Dis.* 2021;21:621. <https://doi.org/10.1186/s12879-021-06205-5>
64. Tang X, Wang N, Liu G, et al. "Psittacosis caused severe community-acquired pneumonia accompanied by acute hypoxic respiratory failure: a multicenter retrospective cohort study from China." *BMC Infect Dis.* 2023;23(1):532. <https://doi.org/10.1186/s12879-023-08283-z>
65. Zhu Z, Wang X, Zhao J, et al. "Clinical characteristics of six patients with Chlamydia psittaci infection diagnosed by metagenomic next-generation sequencing: a case series." *Infect Drug Resist.* 2023;16:869-878. <https://doi.org/10.2147/idr.S393195>